NOVARTIS

In 2024, India's CDSCO approved 19 new drugs, including next-gen therapies for chronic diseases by global majors. Eli Lilly's Mounjaro for diabetes/obesity, Orchid Pharma's Enmetazobactam for resistant bacteria, Cipla's plazomicin for UTIs, Sun Pharma's Etifoxine for anxiety, Dr Reddy's Elobixibat for constipation, and Zydus/Lupin's Vonoprazan for stomach ulcers were notable. New cancer drugs like Eli Lilly's Retevmo and Zydus's nelarabine were also approved.

Borealis Biosciences appoints Christian Hordo as CEO, raises $30M in Series A extension led by Westlake BioPartners, and adds three new board directors: David Allison, Ph.D., Tom Frohlich, and Catherine Thut, Ph.D. The company aims to develop RNA therapeutics for kidney diseases with $180M in capital.

A study found brolucizumab non-inferior to aflibercept in treating DME, with superior anatomic outcomes. Both drugs showed similar adverse event rates. The meta-analysis underscores the need for further trials to assess safety outcomes for brolucizumab as a DME treatment alternative.

Sam Isaly, manager of Finsbury Worldwide Pharmaceutical, is cautious about biotechnology stocks' short-term prospects, despite their profit potential. He emphasizes maintaining exposure due to compelling investment opportunities, with accelerating drug discovery. The trust invests 20-40% in smaller-cap biotech and 60-80% in larger-cap pharma, more optimistic about the latter. Top holdings include Pfizer, Sanofi-Synthelabo, Novartis, Altana, and Orchid BioSciences. The trust's NAV rose 47.2% in six months, outperforming its benchmark.

Novo Holdings completes $16.5B Catalent Pharma Solutions buyout. Merck pays $112M upfront for obesity pill. Ottimo Pharma raises $140M for cancer therapy. Novo Nordisk invests $1.2B in Denmark factory. Angitia Biopharmaceuticals raises $120M for musculoskeletal candidates. Novartis closes MorphoSys sites, laying off 330. SiteOne Therapeutics secures $100M for non-opioid pain drugs. Novo Nordisk's obesity drug underperforms. Bristol Myers Squibb invests $100M in BioArctic's Alzheimer antibodies. Sudan's healthcare collapses. Tonix Pharmaceuticals files NDA for fibromyalgia drug. Neurocrine Biosciences wins FDA approval for Crenessity. Edgewise Therapeutics discusses accelerated approval for Becker muscular dystrophy. FDA places partial hold on PepGen's Duchenne therapy. Checkpoint Therapeutics' immunotherapy approved. WHO opens Academy in Lyon. GSK's Jemperli earns FDA Breakthrough status. Sanofi's duvakitug shows remission in ulcerative colitis. Sandoz agrees to $275M settlement over drug pricing. Pfizer projects 2025 earnings. Mesoblast's Ryoncil approved as 1st MSC therapy for graft-vs-host disease.

The article explores the moral crisis in healthcare, questioning the distinction between killing and letting die in a profit-driven system. It recounts personal experiences with corporate corruption in the pharmaceutical industry and discusses how modern bureaucracies perpetuate harm through detachment and specialization, echoing Hannah Arendt's concept of the banality of evil. The piece critiques the healthcare and pharmaceutical industries for prioritizing profit over patient care, and calls for a reimagining of healthcare as a collective responsibility.

The global targeted protein degradation market is projected to grow from USD 0.548 billion in 2023 to USD 4.37 billion by 2034, driven by precision medicine, drug discovery investments, and technological advancements. PROTACs lead the market, with molecular glues expected to grow fastest. Therapy development dominates applications, particularly in cancer and neurodegenerative diseases. Pharmaceutical & biotechnology companies are the largest end-users. North America leads in revenue, while Asia-Pacific shows the highest growth rate.

The 'Meningitis - Global Clinical Trials Review, 2024' report by ResearchAndMarkets.com offers an overview of meningitis clinical trials, including trial numbers, enrollment, regions, countries, phases, statuses, and sponsor types. It highlights prominent drugs and companies involved, providing insights into global clinical trials landscape and enrollment trends.

Ionis Pharmaceuticals' Tryngolza is the first FDA-approved treatment for familial chylomicronemia syndrome (FCS). FDA senior advisor Robert Temple to retire. Zealand Pharma's glepaglutide for short bowel syndrome rejected, requiring an additional trial. Sangamo grants Astellas rights to use a viral capsid for gene therapy delivery. BioAge Labs partners with Novartis to discover drug targets for age-related illnesses.